Dabigatran/P-glycoprotein (P-gp) Inducers Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may lower the amount of dabigatran in your blood.
What might happen:
Your dabigatran may not work as well and your risk of an unwanted blood clot may increase.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor and pharmacist) know that you are taking these medicines together, if you have taken carbamazepine, phenytoin, rifampin, or St. John's wort in the previous week, or if you stop taking carbamazepine, phenytoin, rifampin, or St. John's wort. Your doctor may want to change you to a different medication to prevent blood clots, or adjust the dose of your dabigatran.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Pradaxa (dabigatran etexilate mesylate) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. March, 2018.
- 2.Pradaxa (dabigatran etexilate mesilate) UK summary of product characteristics. Boehringer Ingelheim Limited August 18, 2011.
- 3.Pradax (dabigatran etexilate mesilate) Canadian prescribing information. Boehringer Ingelheim June 13, 2011.
- 4.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
- 5.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
- 6.Wiggins BS, Northup A, Johnson D, Senfield J. Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. Pharmacotherapy 2016 Feb 5.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.